OmniAb, Inc.
OABIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 27, 2025 | RBC Capital | $4.00(+62%) | $2.47 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| StoneX | maintain | Buy | Oct 7, 2026 |
| Leerink Partners | maintain | Outperform | Oct 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2026 |
| RBC Capital | maintain | Outperform | Aug 7, 2025 |
| Benchmark | maintain | Buy | May 12, 2025 |
| RBC Capital | maintain | Outperform | Mar 27, 2025 |
| Benchmark | maintain | Buy | Mar 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| Benchmark | maintain | Buy | Nov 14, 2024 |
| Benchmark | maintain | Buy | Aug 19, 2024 |
| RBC Capital | maintain | Outperform | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| Benchmark | maintain | Buy | May 14, 2024 |
| Truist Securities | maintain | Buy | Mar 26, 2024 |
| Benchmark | maintain | Buy | Mar 22, 2024 |
| RBC Capital | maintain | Outperform | Mar 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2024 |
| Benchmark | maintain | Buy | Nov 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| Benchmark | maintain | Buy | May 12, 2023 |
| Benchmark | maintain | Buy | Apr 21, 2023 |
| Craig-Hallum | maintain | Buy | Apr 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2023 |
| Cowen & Co. | maintain | Outperform | Feb 22, 2023 |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.12| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 30, 2026 | $-0.12 | $-0.13 | $4.0M | $3.5M |
| Aug 6, 2026 | $-0.05 | $-0.12 | $13.4M | $4.7M |
| May 7, 2026 | $-0.06 | $-0.10 | $14.4M | $5.6M |
| Mar 4, 2026 | $-0.11 | $-0.08 | $8.4M | $9.0M |
| Nov 4, 2025 | $-0.14 | $-0.14 | $2.2M | $5.6M |
| Aug 6, 2025 | $-0.15 | $-0.14 | $3.9M | $5.6M |
| May 8, 2025 | $-0.17 | $-0.17 | $4.2M | $4.5M |
| Mar 18, 2025 | $-0.12 | $-0.13 | $10.8M | $6.5M |
News
OmniAb has reached self-sustaining cash flow, no longer requiring investor funding to operate, with 2026 projected as break-even for net cash usage. OABI's portfolio model offers contractually protected options on hundreds of programs, with over $3 billion in potential milestones and average royalty rates around 3.4%. The Lilly ion channel partnership and a robust late-stage pipeline signal validation and near-term catalysts, including up to 19 clinical trial readouts through 2027.
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
OmniAb NASDAQ: OABI reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early commercial progress for its xPloration B-cell screening platform.
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders w…
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Stifel Healthcare Conference Date: Wednesday, November 11, 2026 2026 Truist Securities BioPharma Symposium Date: Thursday, November 12, 2026 Jefferies London Healthcare Conference Date: November 16–19, 2026 Craig-…
OmniAb NASDAQ: OABI Chief Financial Officer Kurt Gustafson outlined the company's antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than developing drugs internally.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What…
OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its I
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introduces the OmniTides™ peptide discovery platform and brand. “We look forward to bringing together our inv…
Bank of America Corp DE acquired a new stake in OmniAb, Inc. (NASDAQ: OABI) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 149,493 shares of the company's stock, valued at approximately $368,000. Bank of America Corp DE owned
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from OmniAb's executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and …
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced m
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced management's participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026 H.C. Wainwright 28th Annual Global Investment Conference Date: Tuesday, September 15, 2026 The Nasdaq/LD Micro Summit will take place at the Nasdaq …
OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executiv…
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with…